These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31538327)

  • 21. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
    Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
    Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
    Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
    Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
    J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
    Hochhaus A; Masszi T; Giles FJ; Radich JP; Ross DM; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; García-Gutiérrez V; Gattermann N; Wiktor-Jedrzejczak W; le Coutre PD; Martino B; Saussele S; Menssen HD; Deng W; Krunic N; Bedoucha V; Saglio G
    Leukemia; 2017 Jul; 31(7):1525-1531. PubMed ID: 28218239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.
    Yue Y; Gui X; He X; Chen Y; Pan J; Qiu H; Wu D; Chen S; Guo L; Cen J
    Hematology; 2016 May; 21(4):213-7. PubMed ID: 26183593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
    Gugliotta G; Castagnetti F; Breccia M; Levato L; D'Adda M; Stagno F; Tiribelli M; Salvucci M; Fava C; Martino B; Cedrone M; Bocchia M; Trabacchi E; Cavazzini F; Usala E; Russo Rossi A; Bochicchio MT; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G;
    Haematologica; 2015 Sep; 100(9):1146-50. PubMed ID: 26113419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
    Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
    Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
    Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
    Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Kantarjian HM; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Boquimpani C; Pasquini R; Clark RE; Dubruille V; Flinn IW; Kyrcz-Krzemien S; Medras E; Zanichelli M; Bendit I; Cacciatore S; Titorenko K; Aimone P; Saglio G; Hochhaus A
    Leukemia; 2021 Feb; 35(2):440-453. PubMed ID: 33414482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.
    Rios SJ; Martínez-Montesinos L; Aroca C; Teruel-Montoya R; Ferrer-Marín F
    J Assist Reprod Genet; 2020 Oct; 37(10):2473-2476. PubMed ID: 32766925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 35. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
    Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A
    Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
    Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
    Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
    Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.